Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2CNS 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 132Carcinoma, Transitional Cell 92Carcinoma, Non-Small-Cell Lung 84Urinary Bladder Neoplasms 81Melanoma 75Squamous Cell Carcinoma of Head and Neck 50Prostatic Neoplasms 49Colorectal Neoplasms 41Ovarian Neoplasms 36Stomach Neoplasms 35Triple Negative Breast Neoplasms 33Neoplasm Metastasis 32Uterine Cervical Neoplasms 31Neoplasms 28Kidney Neoplasms 27Breast Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Lung Neoplasms 26Pancreatic Neoplasms 23Carcinoma, Hepatocellular 23Esophageal Neoplasms 21Head and Neck Neoplasms 20Endometrial Neoplasms 18Small Cell Lung Carcinoma 16Carcinoma, Merkel Cell 11Mesothelioma 9Cholangiocarcinoma 9Ureteral Neoplasms 8Sarcoma 8Carcinoma, Ovarian Epithelial 8

Interventions

Blood Specimen Collection 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3Surveys and Questionnaires 2Prednisone 2Positron-Emission Tomography 2Magnetic Resonance Imaging 2Injections 2vistusertib 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1pembrolizumab 1lortalamine 1ioflupane 1gossypol acetic acid 1carbon-11 acetate 1abiraterone 1Waiting Lists 1Urine Specimen Collection 1Urination 1Transcutaneous Electric Nerve Stimulation 1Therapeutics 1Specimen Handling 1Referral and Consultation 1Prostatectomy 1Preoperative Exercise 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Observation 1Music Therapy 1Multiparametric Magnetic Resonance Imaging 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × pembrolizumab × Genitourinary × Clear all
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡